ReviewFrontiers in neuroscience2025
The CB1 receptor: linking impulsivity and substance use disorder.
Review in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cannabinoid receptor type 1 (CB1R) is the most widely expressed G protein-coupled receptor in the brain, with high concentrations in the basal ganglia, hippocampus, and cerebellum. Predominantly localized in presynaptic terminals, CB1R modulates synaptic transmission through retrograde endocannabinoid signaling. Its expression follows an ontogenetic trajectory, with region- and age-specific patterns that are particularly dynamic during adolescence. This developmental window is characterized by marked neuroplasticity and heightened impulsivity, a trait closely associated with increased vulnerability to substance use disorders (SUDs). While the prefrontal cortex has traditionally been viewed as the primary locus of self-control, growing evidence supports a broader regulatory network involving CB1R-rich subcortical structures. In particular, the hippocampus and cerebellum contribute to the modulation of impulsive behavior through their connectivity with prefrontal and limbic circuits. CB1R signaling in these regions influences decision-making, reward sensitivity, and response inhibition-all processes critical to the emergence of impulsive traits and drug-seeking behavior. This review integrates preclinical and clinical evidence to propose a distributed CB1R-regulated neurocircuit that underlies impulsivity and mediates risk for SUDs. We highlight adolescence as a critical period during which CB1R ontogeny may transiently unbalance inhibitory control systems, creating a neurobiological substrate for risky behaviors. Furthermore, we identify key knowledge gaps, including the underexplored ontogeny of CB1R in the cerebellum and its functional implications in addiction vulnerability. Understanding the dynamic role of CB1R across development and brain regions offers a more comprehensive model of impulsivity and its pathological escalation into substance use. This perspective may inform translational strategies targeting the endocannabinoid system for early prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.